|AMEX: CATX||Healthcare / Medical Devices & Instruments / USA|
|0.3600||+0.0020||+0.56%||Vol 20.23K||1Y Perf -|
|Feb 27th, 2023 09:30 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||Strong Buy 1.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||0.00||Earnings Rating||—|
|Market Cap||100.32M||Earnings Date||9th May 2023|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th May 2023|
|Estimated EPS Next Report||-0.01|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||0|
|Avg. Monthly Volume||0|
|Avg. Quarterly Volume||0|
Isoray. (DE) (AMEX: CATX) stock closed at 0.5869 per share at the end of the most recent trading day (a 0.56% change compared to the prior day closing price) with a volume of 20.23K shares and market capitalization of 100.32M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 43 people. Isoray. (DE) CEO is Lori A. Woods.
The one-year performance of Isoray. (DE) stock is %, while year-to-date (YTD) performance is 45.69%. CATX stock has a five-year performance of -14.41%. Its 52-week range is between 0.1922 and 0.4499, which gives CATX stock a 52-week price range ratio of %
Isoray. (DE) currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -%, a ROC of -% and a ROE of -%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $- revenue per share.
Of the last four earnings reports from Isoray. (DE), there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.01 for the next earnings report. Isoray. (DE)’s next earnings report date is 09th May 2023.
The consensus rating of Wall Street analysts for Isoray. (DE) is Strong Buy (1), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Isoray. (DE) stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Isoray. (DE) has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Isoray. (DE) has a Neutral technical analysis rating based on Technical Indicators (ADX : 37.79, ATR14 : 0.03, CCI20 : -38.83, Chaikin Money Flow : 0.14, MACD : 0.05, Money Flow Index : 46.04, ROC : -7.00, RSI : 33.87, STOCH (14,3) : 26.67, UO : 46.89, Williams %R : -73.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Isoray. (DE) in the last 12-months were: Jennifer Streeter (Option Excercise at a value of $28 925), Jonathan R. Hunt (Buy at a value of $43 662), Lori A. Woods (Buy at a value of $55 770), Mark Austin (Buy at a value of $5 384)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Isoray Inc offers is a medical technology company. The company designs and develops personalized brachytherapy products that provide a more cost-effective cancer treatment. It is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. Isoray derives most of its revenue from the United States of America.
CEO: Lori A. Woods
Telephone: +1 509 375-5329
Address: 350 Hills Street, Richland 99354, WA, US
Number of employees: 43
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.